1[1]Reissmann PT, Koga H, Figlin RA, et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small cell lung cancer. Lung cancer study group. J Cancer Res Clin Oncol, 1999,125:61～70.
2[2]Malusecka E, Zborek A, Krzyzowska-Gruca S. Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: An immunohistochemical study. Folia Histochem Cytobiol, 1999,37:19～24.
3[3]Keum JS, Kong G, Yang SC, et al. cyclin D1 overexpression is an indicator of poor prognosis in respectable non-small cell lung cancer. Br J Cancer, 1999,81:127～33.
4[4]Caputi M, Groeger AM, Esposto V, et al. Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am J Respir Cell Mol Biol, 1999,20:746～50.
5[5]Mishina T, Dosaka A, Akita H, et al. cyclin D1 expression in non-small cell lung cancers: Its association with altered p53 expression, cell proliferation and clinical outcome. Br J Cancer, 1999,80:1289～95.
7[7]Lonardo F, Rusch V, Langenfeld J, et al. Overexpression of cyclin D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res, 1999,59:2470～6.
8[8]Rao SS, Chu C, Khotz DS. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic-helix-loop-helix regulators. Mol Cell Biol, 1994,14:5259～67.
9[9]Kong LF, Yin PZ, Liu ZG, et al. A study on p16, pRb, cdk4 and cyclin D1 expression in non-small cell lung cancers. Cancer Lett, 1998,130:93～101.
